Sequenta, a biotech company backed by VC firms like Foresite Capital Management, Mohr Davidow Ventures and Index Ventures, has secured new funding from Celgene Corporation (NASDAQ: CELG) and other strategic investors. The new investment will support incorporation of the company's ClonoSIGHT minimal residual disease test into clinical trials of medicines in development for various blood cancers. Sequenta last raised a $20 million Series C round at a $120 million valuation in July 2013. That valuation more than doubled the company's worth from its 2012 $17 million Series B financing ($48 million). Sequenta initially raised $2.1 million of Series A funding at a $15 million valuation in 2009.